Robocath’s Robotic-Assisted Solution R-One Gets CE Mark for Treating Coronary Diseases

R One Robotic assisted angioplasty
Image: Robocath

Robocath, a Rouen, France-based company that develops robotic systems for treating cardiovascular diseases, won CE certification for its R-One™ robotic device. The CE approval now allows the company to start commercializing its product in Europe and the Middle East.

Related Borns, AI-Powered Minimally Invasive Surgery Has Huge Prospects in Healthcare

The R-One is a robotic-assisted coronary angioplasty system that enhances the existing methods of stenting (angioplasty), allowing interventional cardiologists to apply precision technologies during the procedure.

This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed, reports Robocath.

R-One is designed to operate with precision and perform specific movements creating better interventional conditions. The system is compatible with market leading devices and cath labs.

Robotic angioplasty machine
Image: Robocath

“The whole Robocath team is proud to have taken this major step forward in our development, which comes just a few days after our first sale of a training robot to the Medical Training & Testing Center in Rouen. Our entry into the market for interventional vascular robotics represents a substantial opportunity for growth,” said Philippe Bencteux, MD, chairman and founder of Robocath. “There is the potential for the R-One™ solution to be installed in more than 3,000 procedure rooms, performing around 1.6 million interventions each year in Europe alone. Building on our CE mark, we expect to finalize a number of strategic distribution partnerships very shortly in high potential geographic areas, with a Europe and Middle-East wide launch expected in 2020.”

Related This “Smart Stent” Can Monitor Blood Flow and Detect Narrowing of Artery

Founded in 2009 by Dr. Bencteux, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer, thanks to reliable technologies, while complementing manual interventions. The company aims to become the world leader in vascular robotics and develop remote treatment of vascular emergencies, guaranteeing the best care pathway for all.